First Line Therapy for Patients With Metastatic Breast Cancer

PHASE2TerminatedINTERVENTIONAL
Enrollment

123

Participants

Timeline

Start Date

February 1, 2008

Primary Completion Date

December 11, 2012

Study Completion Date

May 31, 2013

Conditions
Metastatic Breast Cancer
Interventions
DRUG

ABI-007

100 mg/m\^2 ABI-007 weekly for 3 weeks followed by 1 week rest

Trial Locations (14)

Unknown

BC Cancer Agency-Burnaby, Burnaby

Lions Gate Hospital, North Vancouver

B.C.C.A Vancouver Island Center, Victoria

Dr. H. Bliss Murphy Cancer Center, St. John's

The Royal Victoria Hospital, Barrie

London Regional Cancer Centre, London

Mount Sinai Hospital, Toronto

St. Michael's Hospital, Toronto

Toronto Synnybrook Cancer Centre, Toronto

Windsor Regional Hospital, Windsor

Hospital de la Cite-de-la Sante-de-Laval, Laval

Centre Hospitalier de l'Universite de Montreal-Hotel-Dieu, Montreal

McGill University, Montreal

CHA: Saint Sacrement Hospital, Québec

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT00456846 - First Line Therapy for Patients With Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter